Virtual Library
Start Your Search
Kentaro Nakata
Author of
-
+
EP1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 206)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.16-41 - Lung Lobectomy for Elderly Patients Over 85 Years Old Is a Risk of a Complication and Long-Term Hospitalization Compared with Sublobar Resection (Now Available) (ID 1360)
08:00 - 18:00 | Presenting Author(s): Kentaro Nakata
- Abstract
Background
The increased number of elderly patients with non-small lung cancer underwent lung resection, though the clinical outcome has remained unclear. In this study, we reviewed the postoperative complications and clinical outcome after lung resection in elderly patients over 85 years old with lung cancer, defied as “very elderly patients”.
Method
Among patients who underwent lung surgery for non-small cell lung cancer (NSCLC from 2012 to 2019 in our institute, a total 24 patients were enrolled for this retrospective study.
Result
During the study period, 24 elderly patients (mean age, 87.3) underwent lung resection, consisting of 14 female and 11 male, 19 adenocarcinomas and 5 non-adenocarcinomas, and 19 c-Stage 0: 1, IA: 16, IB: 3, IIA: 2, IIB: 1, IIIA:1[KS1] (based on UICC 7th edition), and 12 sublobar surgery (6 wedge resections and 6 segmentectomies) and 12 lobectomy. Perioperative complications were observed in 8 patients, and the average hospitalization days are 23.4 days. Next, patients were Stratified by the surgical procedure . The clinical stage is, in limited resection group,cStage 0: 1, 1A: 8, 1B: 3, otherwise in lobectomy group, cStage1A: 8, 1B: 0, 2A: 2, 2B: 1, 3A:1[KS2] . The procedures underwent complete video assisted thoracic surgery are 6 in sublobar resection, 3 in lobectomy. Average operation time is 168 minutes in limited resection, 207 minutes in lobectomy, and blood loss is 48.8 ml and 67.5 ml, respectively. No perioperative mortality was observed within 30 days after surgery. There are more complications in lobectomy group than in limited resection group (50.0%, 25.0%), although the p value was not significant ( p = 0.22). [KS3] The patients need HOT after surgery is one in limited resection, two in lobectomy. Especially the frequency of onset of arrhythmia requiring treatment is high, 33.3%, in lobectomy group and one case needs implanting a pacemaker. On the other a patient in lobectomy group onsets appendicitis after thoracic surgery and the patient is proceeded appendectomy. The average hospitalization days in lobectomy group, 32.5 days, are longer than in limited resection group, 14.3 days.( p = 0.20)
Conclusion
Lung lobectomy in very elderly patients is associated with postoperative complications and prolonged hospitalization compared with sublobar surgery.
-
+
P1.03 - Biology (ID 161)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Biology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.03-16 - Anti-Tumor Effect of Pan-RAF Inhibitor in NSCLC Cells Harboring BRAF Mutation (Now Available) (ID 1206)
09:45 - 18:00 | Author(s): Kentaro Nakata
- Abstract
Background
BRAF mutation occurs in 0.5-3% of lung adenocarcinoma and acts as an oncogenic driver. Dabrafenib (BRAF inhibitor) combined with trametinib (MEK inhibitor) has shown substantial antitumor effect in patients with non-small-cell lung cancer (NSCLC) harboring BRAF V600E mutation. However, in patients with NSCLC harboring BRAF non-V600E mutation, there are few reports of effective targeted therapy. LY3009120, a newly discovered pan-RAF inhibitor, showed strong anti-tumor effect in BRAF-mutant cancers, such as melanoma, colorectal and pancreatic cancers in preclinical studies. In this study, we evaluated the anti-tumor effect of LY3009120 in BRAF-mutant NSCLC cells.
Method
We examined the sensitivity of LY3009120 against normal bronchial cells BEAS-2B which ectopically overexpressing wild-type or mutant BRAF. Human cDNAs encoding full-length BRAF (wild-type and its variants V600E and G469V) were inserted into the pIDT-SMART (C-TSC) vector, pCMViRTSC. In addition, we treated four BRAF-mutant NSCLC cell lines, one BRAF-mutant colorectal cancer cell line, and one KRAS-mutant cell line with LY3009120. The type of BRAF mutation consisted of V600E, L597V, G469A, and G466V. We determined cell proliferation by MTS assay and calculated the IC50 values. We also performed Western blotting to investigate downstream signaling pathways.
Result
BEAS-2B cells ectopically overexpressing wild-type BRAF or mutants (V600E and G469V) showed constitutive auto phosphorylation of BRAF and activation of downstream signaling by Western blotting. The IC50 values in BRAF mutant cell lines ranged from 9.4nM to 1,193nM, which suggests strong anti-tumor effect of LY3009120. This effect was observed regardless of the type of BRAF mutation, including non-V600E mutation. On the other hand, LY3009120 did not show anti-tumor effect in KRAS-mutant cell (IC50 value, 6,948nM). LY3009120 suppressed the phosphorylation of downstream MEK and ERK activation in BRAF-mutant cell lines by Western blotting.
Conclusion
LY3009120 showed strong anti-tumor effect in NSCLC cells harboring BRAF mutation regardless of the type of mutation, suggesting that LY3009120 can be a promising therapeutic option in the treatment of NSCLC harboring BRAF mutation.
-
+
P1.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 186)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Treatment in the Real World - Support, Survivorship, Systems Research
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
-
+
P1.16-35 - The Prognostic Impact of Sarcopenia on the Clinical Outcome of Thoracic Surgery for Non-Small Cell Lung Cancer in Elderly Patients (ID 1544)
09:45 - 18:00 | Author(s): Kentaro Nakata
- Abstract
Background
The elderly patients who undergo surgery for non-small cell lung cancer (NSCLC) is increasing in Japan whereas they are at high risk for surgery because of weakness of physical strength and increased comorbidity. Skeltal muscle depletion, referred to as sarcopenia, has recently been identified as a risk factor of poor clinical outcomes after surgery in the patients with various malignancies including NSCLC. We investigated the impact of sarcopenia on the clinical outcome of thoracic surgery for NSCLC in elderly patients.
Method
We enrolled 259 patients over 65 years old with NSCLC who underwent pulmonary resection (lobectomy or segmentectomy) without any induction treatment before surgery in our hospital during 2012 to 2015. Sarcopenia was assessed by the psoas muscle mass index (PMI, cm2/m2) using the computed tomography imaging at the third lumbar vertebra level before surgery. Postoperative complications, which were observed within 30days after surgery, were classified according to Clavien-Dindo classification. Overall survival (OS) was evaluated by the Kaplan-Meier method with log-rank test (univariate analyses) and by the cox proportional hazard model (multivariate analyses).
Result
Median age was 73 years old (65 - 92). One hundred fifty-five (60%) patients were male. Two hundred nine (81%) patients were cStage0 or I. Fifty-seven (22%) patients were squamous cell carcinoma (SCC). Postoperative pneumonia, arrhythmia, and delirium were observed in 17 (7%), 35 (14%) and 17 (7%) patients, respectively. Median follow-up was 48.7 months (range 3.0 – 79.6). Using the cutoff values as previously reported, 179 (69%) and 80 (31%) patients were diagnosed as sarcopenic and non-sarcopenic, respectively. Male and ever smoker were significantly more frequent in the sarcopenic patients than the non-sarcopenic patients (P < 0.001 and P = 0.018, respectively). The sarcopenic patients showed the trend of high incidence of Postoperative complications, however, there was no significant difference in OS between the sarcopenic and non-sarcopenic patients. Next, we performed the subgroup analysis to elucidate the prognostic factors only in the elderly sarcopenic patients. Among 179 sarcopenic patients, multivariate analysis including statistically significant factors in the univariate analysis revealed that the patients with restrictive lung disease, advanced cStage, postoperative pneumonia and delirium were inferior in OS [Hazard Ratio, 11.1, 3.6, 5.3 and 4.6; 95% confidence interval, 1.6 to 68.1, 1.1 to 13.0, 1.4 to 20.0 and 1.1 to 16.5; P= 0.011, 0.037, 0.017 and 0.041], suggesting the importance of the intensive perioperative management to avoid complications.
Conclusion
Perioperative complications are significantly associated with the prognosis of the sarcopenic elderly patients with NSCLC. Intensive perioperative management is mandatory for NSCLC patients with sarcopenia to improve the clinical outcome after thoracic surgery.
-
+
P2.08 - Oligometastatic NSCLC (ID 172)
- Event: WCLC 2019
- Type: Poster Viewing in the Exhibit Hall
- Track: Oligometastatic NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
-
+
P2.08-03 - Clinical Outcome of Patients with Recurrent Non-Small Cell Lung Cancer After Trimodality Therapy (ID 2569)
10:15 - 18:15 | Author(s): Kentaro Nakata
- Abstract
Background
Trimodality therapy, consisting of induction chemoradiotherapy (CRT) followed by surgery, is a potential treatment option for patients with locally advanced (LA) non-small cell lung cancer (NSCLC), such as N2-3, bulky N1, or T3-4 stage disease. However, even after completing this intensive treatment, postoperative recurrence will develop in a subset of patients. Patients with distant metastatic recurrences are generally considered to have systemic disease, which is regarded as incurable. Nevertheless, some patients have a relatively good prognosis following this treatment, even after postoperative recurrence.
Method
We analyzed the records of 182 patients with LA-NSCLC who were treated with trimodality therapy between 1999 and 2017 to review the clinical course of those patients and to identify the factors associated with favorable clinical outcome after recurrence. In this study, oligometastasis was defined as one to three metastatic lesions in the brain, or an isolated extracranial metastatic lesion.
Result
In 182 patients patients who underwent trimodality therapy for LA-NSCLC, the median follow-up period after the beginning of CRT was 50 months, the median age was 61 years (range, 31–78 years), and Recurrence developed after trimodality therapy in 65 patients (35.7%). The median recurrence-free interval, being the period between the administration of trimodality therapy for the primary tumor and initial recurrence, was 11 months (range, 4.1–73.9 months). Of the 62 of these patients able to be assessed retrospectively, The brain was the most frequent location of recurrence (31%), followed by the lung (27%), lymph nodes (24%), and bone (15%). Twenty-eight had oligometastatic recurrence and 30 underwent local treatment with curative intent. Local treatment was most frequently given to patients with oligometastatic recurrence (P < 0.001). The median post-recurrence survival (PRS) was 15.1 months, and the 2-year PRS rate was 57%. Patients who received local treatment showed better PRS (P = 0.004). The presence of liver metastasis (P = 0.003), bone metastasis (P = 0.034), or dissemination (P < 0.0001) were associated with worse PRS.
Conclusion
The survival of patients who received aggressive local treatment for postoperative recurrence after trimodality therapy for LA-NSCLC was better than that of patients who did not.
